NICE needs more rimonabant data

Rimonabant should not be used for the treatment of obese and overweight adults, says NICE.

More information on how the drug compares to diet and exercise, orlistat and sibutramine with regards to cost effectiveness is needed from manufacturers Sanofi Aventis, claimed NICE in a draft technology appraisal issued last week.

NICE also wants an assessment of the drug using the 5 per cent weight loss continuation rule to treatment with rimonabant at three, six, nine and 12 months.

Jeni Wilson, head of communications at Sanofi Aventis said: 'The consultation document represents the preliminary feedback of the appraisal committee and is not formal guidance on this technology.

'The preliminary thoughts of the committee may change after consultation.'

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GMC sign

Overseas-graduate GPs fare worse in medical tribunals due to lack of legal help

UK GPs who graduated overseas face worse outcomes in GMC cases because they are far...

Woman using HRT patch

Practical advice for GPs on prescribing HRT

GP menopause specialists Dr Louise Newson and Dr Olivia Jones provides an overview...

Vaccination tracker

UK COVID-19 vaccination programme tracker

GPs across the UK have led the largest-ever NHS vaccination programme in response...

NHS logo on tiled wall

PCNs falling short on 26,000 staff target and need more flexibility, GPs warn

Government plans to bring in 26,000 staff by 2024 to support general practice are...

Talking General Practice logo with picture of Dr Ed Cantelo and Dr Tommy Perkins

Podcast: How two GPs set up a business to advise doctors about finance

Talking General Practice speaks to GPs Dr Tommy Perkins and Dr Ed Cantelo from Medics...

Houses of Parliament

MPs from all parties call on government to do more on GP shortage

MPs from all parties have warned the government that it needs to do more to tackle...